For over two decades, enzyme replacement therapy (ERT) with alglucosidase alfa has enabled the treatment of patients with Pompe disease by replacing the missing alpha-glucosidase enzyme through infusions of purified recombinant human alpha-glucosidase (rhGAA). Here, GAA is linked to glycogen storage disease II.